The device was not returned for analysis.A review of the lot history record revealed no manufacturing nonconformities that would have contributed to this complaint.Additionally, a review of the complaint history of the reported lot revealed no other incidents.The investigation determined that the reported deployment difficulty and stent shortening were likely the result of anatomical challenges.Forward/pushing motion on the delivery system during stent deployment while attempting to place in the 90% stenosed, moderately tortuous, heavily calcified lesion may have caused shortening of the stent.There is no indication of a product quality issue with respect to the design, manufacture, or labeling of the device.
|
It was reported that the procedure was performed to treat a 90% stenosed, moderately tortuous, and heavily calcified lesion in the superficial femoral artery.A 6fr 45cm sheath was advanced through the 5.5mm vessel.Following pre-dilatation with a 5.5x80mm armada 18 balloon catheter, a 5.5x80mm supera self-expanding stent system (sess) was advanced.During deployment of the sess the stent became compressed greater than 10% and did not cover the entire lesion.The stent remained within the target lesion and the delivery system was removed under fluoroscopy.A 5.5x100mm supera stent was deployed overlapping the existing stent to fully cover the lesion.The patient is doing fine.There were no adverse patient effects and no clinically significant delay in the procedure.No additional information was provided.
|